Company Overview - Amphastar is a biopharmaceutical company focused on developing and manufacturing technically challenging BLAs, NDAs, and ANDAs in injectable, inhalable, and intranasal formulations[37] - The company has a strong base business with approximately $350 million in 2020 revenue and approximately $143 million in 2020 gross profit[37] - Amphastar has a vertically integrated business model, from R&D to clinical trials, manufacturing, marketing, and distribution[6] Product Portfolio and Pipeline - The company has a diverse core of over 20 commercial products, including injectables and MDI products[11] - Amphastar has a robust pipeline of over 20 product candidates, including insulin products, in markets with barriers to entry[37] - Five filed ANDAs with IQVIA sales of approximately $2.4 billion, including AMP-002 with > $300 million IQVIA sales[23] - Five Inhalation ANDAs in development targeting products with IQVIA sales of approximately $8 billion[23] - Three candidates of Insulins with IQVIA sales ~$13 Billion[25] Financial Highlights - The company's net revenue has a CAGR of 13% from 2017 to 2020[14] - Self-funded R&D investment of approximately $280 million in the recent 5 years[18] - As of December 31, 2020, the company had $109684000 in cash, cash equivalents, restricted cash, and short-term investments[36]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 | --- | --- | |------------------------------------------------------------------------------------------------ ...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q2 2020 Earnings Conference Call August 6, 2020 5:00 PM ET Company Participants Dan Dischner – Vice President of Human Resources and Corporate Communications Bill Peters – Chief Financial Officer Tony Marrs – Senior Vice President of Regulatory Affairs and Clinical Operations Conference Call Participants Tim Chiang – Northland Capital Markets David Amsellem – Piper Sandler Rafay Sardar – BMO Capital Markets David Steinberg – Jefferies Tian Sun – Needham & Compan ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 | --- | --- | |----------------------------------------------------------------------------------------------------- ...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2020 Earnings Conference Call May 7, 2020 5:00 PM ET Company Participants Dan Dischner - VP of Corporate Communications Tony Marrs - VP of Clinical Research William Peters - CFO, Treasurer & Senior VP of Finance Conference Call Participants Tim Chiang - Northland Securities Gary Nachman - BMO Capital Markets Lucas Lee - Raymond James David Steinberg - Jefferies Operator [Abrupt Start] All statements on this conference call that are not historical are forward- ...

Table of Contents | --- | |-------------------------------------------------------------------------------------| | | | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | FORM 10-Q | ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 | --- | ...

| --- | --- | |-------|---------------------------------------------------------------------------------| | | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | FORM 10-K | ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File Number 001-36509 AMPHASTAR ...